New Israeli COVID treatment shows promising results in phase 2 trials

The trial, however, was only conducted on 16 patients, nine of whom were in serious condition, while the other seven were in critical condition. Despite the small sample size, the researchers were happy to note that none of the patients had succumbed to the virus, and 14 of the 16 patients were discharged from hospital.

The Israeli company Enlivex Therapeutics announced the trial results for their drug, Allocetra, on Wednesday. They had previously conducted a phase one trial on just five patients, all of whom recovered after taking the medication.

Allocetra is a drug designed to prevent the immune system from overreacting to the presence of a virus, which can sometimes cause more damage to the human body than the actual virus infecting it.

As the coronavirus vaccine is being rolled out around the world, some priority is still being placed on developing effective treatments for those who have contracted and are suffering from the virus.

Enlivex says they will be submitting the drug to regulatory bodies in Europe and North America for further trials.